Malaria: New Treatment is Upcoming
Developed by the Italian Pharmaceutical Company sigma-tau
New Data Confirm the Absence of Side Effects and the Benefit of the Simpler Treatment Schedule
These notable results were presented at the 57th Annual Meeting of the
American Society of Tropical Medicine & Hygiene (ASTMH) held in
"If not promptly and effectively treated, malaria can kill in just a few
days after the onset of symptoms," said Prof. Umberto D'Alessandro, Prince
Leopold Institute of Tropical Medicine,
Developed by sigma-tau, the new ACT meets WHO clinical evidence-based treatment strategy recommendation as it is a medication combining in a single tablet the highly potent artemisinin-based active ingredient which does not stay long in the body with a second antimalarial which stays longer in the body. This combination treatment is to be taken only for three days and facilitates the mutual protection of the two active ingredients against drug resistance.
The results presented in
"The new data," said
sigma-tau's commitment began to become tangible in 2004 when the company
entered into a partnership with Medicines for Malaria Venture, the
sigma-tau is a leading, all Italian capital, international pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve patient well-being and quality of life.
sigma-tau Group has headquarters in Pomezia (
sigma-tau was founded in
sigma-tau SpA consistently invests 16% of its annual turnover in R&D. sigma-tau's 400 R&D staff are currently running 43 R&D projects. A total of 14 NCEs and 12 known molecular entities in 30 different indications are at various stages of development.
Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology.
sigma-tau website: http://www.sigma-tau.it For further information: Press Office Publicis Consultants Italia Virginie Colonna-Foschi Mobile. +39-349-8762101 firstname.lastname@example.org Tel. +39-02-7632091 Fax +39-02-76320940
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.